Ho­mol­o­gy lays off staff, paus­es rare meta­bol­ic dis­ease tri­al de­spite clin­i­cal hold lift

3 years ago
R&D

Pos­i­tive read­out? Pub­lic of­fer­ing: Virid­i­an plans to raise $175M on eye dis­ease ther­a­py da­ta

3 years ago
Financing
R&D

Roche’s Po­livy con­tin­ues its reg­u­la­to­ry dance, will head to FDA for a form of blood can­cer

3 years ago
R&D
Pharma

TYK2 heats up with Ven­tyx eye­ing mid-stage tri­als; Nex­Im­mune cites com­pe­ti­tion in pipeline cull

3 years ago
News Briefing

Gos­sip in Baby­lon: Dig­i­tal health com­pa­ny paints M&A ru­mors as flat-out wrong

3 years ago
Financing
Deals

New Hahn-era texts show the ex­tent of the Trump White House­'s in­volve­ment in vac­cine EUA process

3 years ago
FDA+
Coronavirus

Buy­ing time to catch up on sales, ADC Ther­a­peu­tics takes on $175M loan

3 years ago
Financing

Gilead doles out $280M up­front to re­gain Trodelvy rights in Chi­na, oth­er re­gion­al ter­ri­to­ries

3 years ago
Deals

Two years post-merg­er, Flag­ship’s Sen­da re­fines pipeline and re­plen­ish­es the bank 

3 years ago
Financing
Startups

'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance ...

3 years ago
Deals

UK says it won't pur­chase As­traZeneca's Covid treat­ment due to 'in­suf­fi­cien­t' Omi­cron da­ta — re­ports

3 years ago
Pharma
Coronavirus

Re­silience col­lab­o­rates with the Mayo Clin­ic to man­u­fac­ture rare and com­plex dis­ease drugs

3 years ago
Deals
Cell/Gene Tx

Gilead­'s Trodelvy scores 'sur­prise' OS win in metasta­t­ic breast can­cer, but da­ta will wait for an up­com­ing con­fer­ence

3 years ago
Pharma

Mod­er­na's bi­va­lent Omi­cron vac­cine se­cures reg­u­la­to­ry OK in UK

3 years ago
Pharma
Coronavirus

Emer­gent nets it­self more trou­ble as it re­ceives a warn­ing let­ter from the FDA

3 years ago
Pharma
FDA+

French phar­ma ex­ec says he lied to FDA in at­tempt to steal a No­var­tis weight loss drug

3 years ago
Pharma
Law

Gilead com­mits mil­lions more for HIV health eq­ui­ty ef­forts in south­ern cities

3 years ago
Pharma
Marketing

An an­tibi­otics play­er ax­es staff in wake of PhI­II fail; Hori­zon to fund an­ti­body de­vel­op­ment, with op­tion to buy

3 years ago
News Briefing

Af­ter last year's pub­lic re­jec­tion, Brain­Storm to give ALS cell ther­a­py an­oth­er shot de­spite still flunk­ing a ...

3 years ago
R&D

Pyx­is tak­ing scalpel to pre­clin­i­cal pipeline, stops de­vel­op­ment on half — for now

3 years ago
R&D

Atai prunes pipeline, drops out of part­ner­ships as it takes on $175M loan and fo­cus­es on loom­ing da­ta read­outs

3 years ago
Financing
R&D

Af­ter a huge sale, 'Phar­ma Bro' Mar­tin Shkre­li’s cryp­to to­ken plum­mets

3 years ago
People

Ideaya stock slashed af­ter GSK punts an op­tion

3 years ago
Deals
R&D

Pfiz­er CEO Al­bert Bourla is putting his Covid-19 vac­cine to a per­son­al test. And so far, so good

3 years ago
People
Pharma
First page Previous page 478479480481482483484 Next page Last page
A service from the Financial Times